-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 VbsoiC1BrTO2b2+ryUovK7MMeRcwrPIYAo63BgEpvX0MhNwAbOHSBzgWY2TvCU+u
 ZZ6H3HV57x2unpCcaaWwZA==

<SEC-DOCUMENT>0000950152-08-005567.txt : 20080723
<SEC-HEADER>0000950152-08-005567.hdr.sgml : 20080723
<ACCEPTANCE-DATETIME>20080723162733
ACCESSION NUMBER:		0000950152-08-005567
CONFORMED SUBMISSION TYPE:	S-3/A
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20080723
DATE AS OF CHANGE:		20080723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TRANSCAT INC
		CENTRAL INDEX KEY:			0000099302
		STANDARD INDUSTRIAL CLASSIFICATION:	INSTRUMENTS FOR MEAS & TESTING OF ELECTRICITY & ELEC SIGNALS [3825]
		IRS NUMBER:				160874418
		STATE OF INCORPORATION:			OH
		FISCAL YEAR END:			0327

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-152392
		FILM NUMBER:		08966072

	BUSINESS ADDRESS:	
		STREET 1:		35 VANTAGE POINT DRIVE
		CITY:			ROCHESTER
		STATE:			NY
		ZIP:			14624
		BUSINESS PHONE:		5853527777

	MAIL ADDRESS:	
		STREET 1:		35 VANTAGE POINT DRIVE
		CITY:			ROCHESTER
		STATE:			NY
		ZIP:			14624

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSMATION INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3/A
<SEQUENCE>1
<FILENAME>l32474csv3za.htm
<DESCRIPTION>TRANSCAT, INC. S-3/A
<TEXT>
<HTML>
<HEAD>
<TITLE>TRANSCAT, INC. S-3/A</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>As
filed with the Securities and Exchange Commission on July&nbsp;23, 2008</B>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Registration
No. 333-152392</B>
</DIV>

<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>AMENDMENT
NO. 1<BR>To</B>
</DIV>
<DIV align="center" style="font-size: 18pt; margin-top: 1pt"><B>FORM S-3</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>REGISTRATION STATEMENT<BR>
UNDER THE SECURITIES ACT OF 1933</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>TRANSCAT, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center"><B>Ohio</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>16-0874418</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of incorporation or organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer Identification Number)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>35 Vantage Point Drive<BR>
Rochester, New York 14624<BR>
(585)&nbsp;352-7777</B><BR>
(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal<BR>
executive offices)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Charles P. Hadeed<BR>
President, Chief Executive Officer and Chief Operating Officer<BR>
Transcat, Inc.<BR>
35 Vantage Point Drive<BR>
Rochester, New York 14624<BR>
Tel: (585)&nbsp;352-7777<BR>
Fax: (585)&nbsp;352-7788</B><BR>
(Name, address, including zip code, and telephone number, including area code, of agent for service)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Copies to:<BR>
<B>James M. Jenkins, Esq.<BR>
Harter Secrest &#038; Emery LLP<BR>
1600 Bausch &#038; Lomb Place<BR>
Rochester, New York 14604<BR>
Tel: (585)&nbsp;232-6500<BR>
Fax: (585)&nbsp;232-2152</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Approximate date of commencement of proposed sale to the public: </B>From time to time after this
registration statement becomes effective.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the only securities being registered on this Form are being offered pursuant to dividend or
interest reinvestment plans, please check the following box.&nbsp;<FONT face="Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any of the securities being registered on this Form are to be offered on a delayed or
continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933, other than securities
offered only in connection with dividend or interest reinvestment plans, check the following box.&nbsp;<FONT face="Wingdings">&#254;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is filed to register additional securities for an offering pursuant to Rule
462(b) under the Securities Act, please check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same
offering.&nbsp;<FONT face="Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities
Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering.&nbsp;<FONT face="Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a registration statement pursuant to General Instruction I.D. or a
post-effective amendment thereto that shall become effective upon filing with the Commission
pursuant to Rule 462(e) under the Securities Act, check the following box.&nbsp;<FONT face="Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a post-effective amendment to a registration statement filed pursuant to
General Instruction I.D. filed to register additional securities or additional classes of
securities pursuant to Rule 413(b) under the Securities Act, check the following box.&nbsp;<FONT face="Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate
by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer or a smaller reporting company.
See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated
filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act.
(Check one):</DIV>


<TABLE width="100%" style="font-size: 10pt; margin-top: 0pt">
<TR><TD>Large accelerated filer&nbsp;<FONT face="Wingdings">&#111;</FONT><BR><BR></TD>
<TD align="center">Accelerated filer&nbsp;<FONT face="Wingdings">&#111;</FONT><BR>&nbsp;</TD>
<TD align="center">Non-accelerated filer&nbsp;<FONT face="Wingdings">&#254;</FONT>
<BR>(Do not check if a smaller reporting company)</TD>
<TD align="right">Smaller reporting company&nbsp;<FONT face="Wingdings">&#111;</FONT><BR><BR></TD>
</TR>
</TABLE>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CALCULATION OF REGISTRATION FEE</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom" style="font-size: 0pt">
    <TD width="1%">&nbsp;</TD>
    <TD width="54%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>

    <TD width="1%">&nbsp;</TD>
</TR><TR style="font-size: 1px" valign="bottom">
    <TD nowrap align="left" colspan="23" style="border-bottom: 3px double #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center"><B>Title of each class</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Proposed maximum</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Proposed maximum</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center"><B>of securities to be</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Amount to be</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>offering price</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>aggregate offering</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Amount of</B></TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center"><B>registered</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>registered</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>per share</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>price</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>registration fee</B></TD>
    <TD width="1%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD width="1%" style="border-top: 2px solid #000000">&nbsp;</TD>
                    <TD style="border-top: 2px solid #000000"><DIV style="margin-left:15px; text-indent:-15px">Common Stock, par
value $.50 per
share</DIV></TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 2px solid #000000">247,906</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 2px solid #000000">$</TD>
    <TD align="right" style="border-top: 2px solid #000000">6.53</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 2px solid #000000">$</TD>
    <TD align="right" style="border-top: 2px solid #000000">1,618,827</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 2px solid #000000">$</TD>
    <TD align="right" style="border-top: 2px solid #000000">63.62</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD width="1%" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px" valign="bottom">
    <TD nowrap align="left" colspan="23" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>




<DIV style="margin-top: 3pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>Pursuant to Rule 457(c) of the Securities Act of 1933, the proposed maximum offering
price per share and the proposed maximum aggregate offering price have been computed on the basis
of $6.53 per share, the average of the high and low sales prices of the common stock of the
registrant reported on the NASDAQ Capital Market on July&nbsp;15, 2008.</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>The registrant hereby amends this registration statement on such date or dates as may be
necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in
accordance with </B><B>Section 8(a)</B><B> of the Securities Act of 1933 or until the registration statement
shall become effective on such date as the Securities and Exchange Commission, acting pursuant to
said Section&nbsp;</B><B>8(a)</B><B>, may determine.</B>
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Dated
July&nbsp;23, 2008</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PROSPECTUS</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<IMG src="l32474cl3247401.gif" alt="(TRANSCAT LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Transcat, Inc.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>247,906 Shares of Common Stock</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus relates to the resale of up to 247,906 shares of our common stock, par value
$.50 per share, from time to time, by E. Lee Garelick, a former director of ours. Mr.&nbsp;Garelick,
who served as a member of our board of directors since June&nbsp;1996, retired from the board on May&nbsp;6,
2008. As a result of Mr.&nbsp;Garelick&#146;s retirement from the board, we have agreed to register the
shares covered by this prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Garelick is referred to throughout this prospectus either by name or as the &#147;selling
shareholder.&#148; Mr.&nbsp;Garelick may sell the common stock covered by this prospectus, from time to
time, directly or through agents or dealers, on terms to be determined at the time of sale. The
prices at which he may sell his shares will be determined by the prevailing market price for the
shares at the time of sale or in negotiated transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Garelick will receive all of the proceeds from any sales of our common stock made pursuant
to this prospectus. Accordingly, we will receive no proceeds from sales of our common stock made
pursuant to this prospectus. Mr.&nbsp;Garelick and the company are paying the expenses of registering
the shares covered by this prospectus and preparing this prospectus, but he will pay any selling
expenses incurred by him in connection with the shares of common stock covered by this prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is quoted on the NASDAQ Capital Market under the symbol &#147;TRNS&#148;. On July&nbsp;15,
2008, the closing price of our common stock on the NASDAQ Capital Market was $6.53 per share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Investing in our common stock involves a high degree of risk. Please see the section entitled
&#147;Risk Factors&#148; beginning on page 8 of this prospectus to read about risks you should consider
before buying our common stock.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Neither the Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal offense.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">The
date of this prospectus is July&nbsp;23, 2008.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>TABLE OF CONTENTS</B></U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">INFORMATION CONTAINED IN THIS PROSPECTUS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">i</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SUMMARY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">RISK FACTORS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">USE OF PROCEEDS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SELLING SHAREHOLDER</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">PLAN OF DISTRIBUTION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">LEGAL OPINION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">EXPERTS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">WHERE YOU CAN FIND MORE INFORMATION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">INCORPORATION BY REFERENCE</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>INFORMATION CONTAINED IN THIS PROSPECTUS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In this prospectus, &#147;Transcat,&#148; &#147;the company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Transcat, Inc.,
an Ohio corporation, and its subsidiary, taken as a whole, unless the context otherwise requires.
In this prospectus, the &#147;Securities Act&#148; refers to the Securities Act of 1933, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not authorized any dealer, salesperson or other person to give you any information or
to make any representations to you, other than those contained or incorporated by reference in this
prospectus, in connection with the offer contained in this prospectus and, if given or made, you
should not rely on such information or representations as having been authorized by us.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus does not constitute an offer to sell, or a solicitation of an offer to buy,
securities other than those specifically offered hereby or of any securities offered hereby in any
jurisdiction where, or to any person to whom, it is unlawful to make such offer or solicitation.
The information contained in this prospectus speaks only as of the date of this prospectus unless
the information specifically indicates that another date applies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus has been prepared based on information provided by us and by other sources
that we believe are reliable. In addition, this prospectus summarizes certain documents and other
information in a manner we believe to be accurate, but we refer you to the actual documents, if
any, for a more complete understanding of the documents that we discuss in this prospectus. In
making a decision to invest in our common stock, you must rely on your own examination of the
company and the terms of the offering and the common stock, including the merits and risks
involved.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We incorporate by reference important information into this prospectus. You may obtain the
information incorporated by reference by following the instructions under &#147;Where You Can Find More
Information.&#148; You should carefully read this prospectus as well as additional information
described under &#147;Incorporation by Reference&#148; before deciding to invest in shares of our common
stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are not making any representation to you regarding the legality of an investment in our
common stock by you. You should not consider any information in this prospectus to be legal,
business, tax or other advice. You should consult your own attorney, business advisor and tax
advisor for legal, business and tax advice regarding an investment in our common stock.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->i<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SUMMARY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>The following summary highlights information about the offering of common stock covered by
this prospectus, but it may not contain all of the information that is important to you. You
should read the entire prospectus carefully, including our financial statements incorporated by
reference from the annual and quarterly reports we have filed with the Securities and Exchange
Commission. You should also read &#147;Risk Factors&#148; beginning on page 8 for more information about
important risks that you should consider before investing in our common stock.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Our Company</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transcat is a leading global distributor of professional grade test and measurement
instruments and a provider of calibration, 3-D metrology and repair services primarily to the life
science, manufacturing, utility and process industries. We conduct our business through two
segments: distribution products (&#147;distribution products&#148; or &#147;Product&#148;) and calibration services
(&#147;calibration services&#148; or &#147;Service&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Through our distribution products segment, we market and distribute national and proprietary
brand instruments to approximately 12,500 global customers. Our product catalog (&#147;Master Catalog&#148;)
offers access to more than 25,000 test and measurement instruments, including: calibrators,
insulation testers, multimeters, pressure and temperature devices, oscilloscopes, recorders and
related accessories, from over 200 of the industry&#146;s leading manufacturers including Agilent,
Fluke, GE, Emerson, and Hart Scientific. In addition, we are the exclusive worldwide distributor
for Transmation and Altek products. The majority of the instrumentation we sell requires expert
calibration service to ensure that it maintains the most precise measurements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Through our calibration services segment, we offer precise, reliable, fast calibration, 3-D
metrology and repair services. As of the end of our fiscal year ended March&nbsp;29, 2008, (&#147;fiscal year
2008&#148;), we operated eleven calibration laboratories (&#147;Calibration Centers of Excellence&#148;)
strategically located across the United States, Puerto Rico, and Canada servicing approximately
8,000 customers. Each of our Calibration Centers of Excellence is ISO-9001:2000 and we have adopted
one of the broadest scopes of accreditation in the industry, achieving several international levels
of quality, consistency and reliability. See &#147;Calibration Services Segment&#148; below for more
information.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CalTrak<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, our proprietary documentation and asset management system, is used to
manage the workflow at our Calibration Centers of Excellence. Additionally, CalTrak-Online provides
our customers direct access to calibration certificates, calibration data, and access to other key
documents required in the calibration process. CalTrak<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> has been validated to U.S
federal regulation 21CFR 820.75, which is important to the life science industry, where federal
regulations are particularly stringent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At Transcat, our attention to quality goes beyond the products and services we deliver. Our
sales, customer service and support teams stand ready to provide expert advice, application
assistance and technical support wherever and whenever our customers need it. Since calibration is
an intangible service, we believe that our customers trust the integrity of our people and
processes which form the foundation of our relationships with our customers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Among our customers, and representing approximately 33% of our consolidated revenue, are
Fortune 500/Global 500 companies, including Wyeth, Johnson &#038; Johnson, DuPont, Exxon Mobil, Dow
Chemical, and Duke Energy. Transcat has focused on the life science, manufacturing, utility and
process markets since its founding in 1964. The life science industry, as we define it, includes
pharmaceutical and biotechnology companies, medical device manufacturers, and healthcare service
providers. The process industry has been and continues to be the foundation of our business
competency. The process industry, as we define it, includes petroleum refining, chemical, water
treatment, industrial power, steel, petrochemical, gas and pipeline, textile, pulp and paper, food
and dairy companies.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Distribution Products Segment</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our customers use test and measurement instruments to ensure that their processes, and
ultimately their end product(s), are within specification. Utilization of such diagnostic
instrumentation also allows for continuous improvement processes to be in place, increasing the
accuracies of their measurements. The industrial distribution products industry for test and
measurement instrumentation, in those geographic markets where we predominately operate, is
serviced by broad based national distributors and niche or specialty-focused organizations such as
Transcat.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Most industrial customers find that maintaining an in-house inventory of back-up test and
measurement instruments is cost prohibitive. As a result, the distribution of test and measurement
instrumentation has traditionally been characterized by frequent, small quantity orders combined
with a need for rapid, reliable, and complete order fulfillment. The purchasing decision is
generally made by plant engineers, quality managers, or their purchasing personnel. Products are
generally purchased from more than one distributor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The majority of our products are not consumables, but are purchased as replacements, upgrades,
or for expansion of manufacturing and research and development facilities. Our catalog and sales
activities are designed to maintain a constant presence in front of the customer to ensure we
receive the order when they are ready to purchase. As a result, we evaluate revenue trends over at
least a four quarter cycle as any individual months&#146; revenue can be impacted by numerous factors,
many of which are unpredictable and potentially non-recurring.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that a distribution product customer chooses a distributor based on a number of
different criteria including the timely delivery and the accuracy of orders, consistent product
quality, value added services and price. Value added services include providing technical support
to insure our customer receives the right product for their specific need through application
knowledge and product compatibility. We also provide calibration of product purchases, on-line
procurement, same day shipment of products for in-stock items, a variety of custom product
offerings and training programs. Our customers also get the operational efficiency of dealing with
one distributor for most or all of their product needs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our distribution products segment accounted for approximately 67% of our consolidated revenue
in fiscal year 2008. Within the distribution products segment, our routine business is comprised of
customers who place orders to acquire or to replace specific instruments, which range from less
than $250 to $100,000 per order, with an average of approximately $1,500 per order.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Through our comprehensive Master Catalog, supplemental catalogs, website, opt-in email
newsletter, and other direct sales and marketing programs, we offer our customers a broad selection
of highly recognized branded products at competitive prices. The instruments typically range in
price from $250 to over $25,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During fiscal year 2008, we distributed approximately 1.1&nbsp;million pieces of direct marketing
materials including catalogs, brochures, supplements and other promotional materials, of which
approximately 665,000 were distributed to customer contacts and approximately 450,000 were
distributed to potential customer contacts. Some of the key factors that determine the number of
catalogs and other direct marketing materials received by each customer include new product
introductions, their market segments and the timing, frequency and monetary value of past
purchases.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The majority of our product sales are derived from direct mail and on-line marketing. Our
Master Catalog consists of approximately 700 pages of products relevant to the life science,
manufacturing, utility and process industries. We distribute our Master Catalog to approximately
89,000 existing and prospective customers in the United States and Canada typically every 12
months. The Master Catalog provides standard make/model and related information and is also
available in an electronic format upon request and on-line on our website. Our new customer
acquisition program utilizes smaller catalog supplements that feature new products, promotions, or
specific product categories. The catalog supplements are launched at varying periods throughout the
year; the publications are mailed to approximately 1.0&nbsp;million customers and targeted prospects.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our website provides advanced product search features and downloadable product specification
sheets for our current and prospective customers. Recent updates to our website include a redesign
for search engine optimization, streamlined order entry and the unique ability to add an accredited
calibration of test equipment to an order. As a result of these
efforts, traffic to our
website has increased more than three-fold over the past two years.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The distribution product markets we serve are highly competitive. Competition for sales in
distribution products is quite fragmented and ranges from large national distributors and
manufacturers to small local distribution organizations. Key competitive factors typically include
customer service and support, quality, turn around time, inventory availability, product brand
name, and price. To address our customers&#146; needs for technical support and product application
assistance, and to differentiate ourselves from competitors, we employ a staff of highly trained
technical application specialists. To maintain our competitive position with respect to such
products and services, we continually demonstrate our commitment to our customers by providing
technical training for our employees in the areas described above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that effective purchasing is a key element to maintaining and enhancing our
position as a provider of high quality test and measurement instruments. We frequently evaluate our
purchase requirements and suppliers&#146; offerings to obtain products at the best possible cost. We
obtain our products from more than 230 suppliers of brand name and private labeled equipment. In
fiscal year 2008, our top 10 vendors accounted for approximately 73% of our aggregate business.
Approximately 31% of our product purchases on an annual basis are from Fluke Electronics
Corporation (&#147;Fluke&#148;), which we believe to be consistent with Fluke&#146;s share of the markets we
service.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We plan our product mix to best serve the anticipated needs of our customers whose individual
purchases vary in size. We can usually ship our customers our top selling products the same day
they are ordered. During fiscal year 2008, approximately 88% of orders for our top selling products
were filled with inventory items already in stock. Our distribution operations take place within an
approximate 27,000 square-foot facility located in Rochester, New York. This location serves as our
corporate headquarters and also houses our customer service, sales and administrative functions as
well as a calibration laboratory. Approximately 32,000 product orders are shipped from this
facility annually.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We distribute our products throughout North America and internationally from our distribution
center in Rochester, New York. We maintain appropriate inventory levels in order to satisfy
anticipated customer demand for prompt delivery and complete order fulfillment of their product
needs. These inventory levels are managed on a daily basis with the aid of our sophisticated
purchasing and stock management information system. Our automated laser bar code scanning
facilitates prompt and accurate order fulfillment and freight manifesting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to our direct end-user customers, we also sell products to resellers who then sell
to end-users. Our sales to resellers are typically at a lower gross margin than sales to direct
customers and therefore the percentage of reseller sales to total revenue in any given period can
have an impact on our overall gross profit margin. We believe that these resellers have access,
through their existing relationships, to end-user customers to whom we do not market directly.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since fiscal year 2002, we have been the exclusive worldwide distributor of Altek and
Transmation branded products. In exchange for exclusive distribution rights, we committed to
purchase a minimum amount of Altek and Transmation products from Fluke. Our purchases for calendar
year 2007, as in every calendar year since 2002, exceeded the commitment. By its terms, the
exclusivity agreement terminated on December&nbsp;31, 2007. Fluke has agreed to extend the exclusivity
agreement through December&nbsp;31, 2008 while we negotiate a new agreement beyond calendar year 2008.
The minimum amount of purchases for calendar year 2008 is $4.0&nbsp;million, which we believe will be
achieved based on historical sales trends. In the event that Transcat fails to make the required
purchases, it may lose its right to be the exclusive worldwide distributor.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Calibration Services Segment</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Calibration is the act of comparing a unit or instrument of unknown value to a standard of
known value and reporting the result in some rigorously defined form. After the calibration has
been completed, a decision is made, again based on rigorously defined parameters, on what is to be
done to the unit to conform with the required standards or specifications. The decision may be to
adjust, optimize or repair a unit; limit the use, range or rating of a unit; scrap the unit; or
leave the unit as is. The purpose of calibration is to significantly reduce the risk of product or
process failures caused by inaccurate measurements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The billion-dollar commercial calibration services industry in the United States is extremely
fragmented with companies ranging from nationally accredited organizations, such as Transcat, to
non-accredited, sole proprietors as well as companies that perform their own calibrations in-house.
Our typical customer contact is a technically knowledgeable individual, employed in a mid- to high
level quality, engineering or manufacturing position.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within the calibration industry, there is a broad array of measurement disciplines making it
costly and inefficient for any one provider to invest the needed capital for facilities, equipment
and uniquely trained personnel necessary to perform all calibrations in-house. Our strategy, within
our calibration services segment, has been to focus our investments in the core electrical,
temperature, pressure and dimensional disciplines. Accordingly, in servicing our customers&#146;
calibration needs in these highly technical disciplines, we have historically subcontracted to
outside vendors, including those with unique or proprietary capabilities, 15% to 20% of the
instruments we receive from customers for calibration. These vendor relationships have enabled us
to continue our pursuit of having the broadest calibration offerings to these targeted markets.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe calibration sourcing decisions are based on quality, customer service, turn-around
time, location, documentation, price, and a one-source solution. Our success with customers who
value quality is based on the trust they have in the integrity of our people and processes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transcat&#146;s calibration strategy encompasses two methods to manage a customer&#146;s calibration and
repair needs:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If a company wishes to outsource its calibration needs, we offer an &#147;Integrated Calibration Services
Solution&#148; that provides a complete wrap-around service:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Program management;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Calibration;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Logistics; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Consultation services.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If a company has an in-house calibration operation, we can provide:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Calibration of primary standards;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Overflow capability either on-site
or at one of our Calibration
Centers of Excellence during
periods of high demand; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Consultation and training services.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In either case, we strive to have the broadest accredited calibration offering to our targeted
markets which includes certification of our technicians pursuant to the American Society for
Quality (&#147;ASQ&#148;) standards, complete calibration management encompassing the entire metrology
function, and access to our service offerings.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Overall, the calibration services market is aligned with our strategic focus on quality
accreditations. We believe our calibration services are of the highest technical and quality
levels, with broad ranges of accreditation and registration.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our calibration services segment provides periodic calibration, 3-D metrology and repair
services for our customers&#146; test and measurement instruments. We perform over 125,000 in-house
calibrations annually. These are performed at our eleven Calibration Centers of Excellence or at
the customer&#146;s location. During fiscal year 2008, services completed by our Calibration Centers of
Excellence represented approximately 80% of our calibration services
segment revenue, while 18% of
the revenue was derived from calibration services that were subcontracted to outside vendors. Our
calibration services segment accounted for approximately 33% of our total fiscal year 2008
consolidated revenue.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The calibration services industry has its origins in the military. Approximately 60% of our
calibration technicians and laboratory managers received metrology training in the military or have
had calibration experience with the military prior to joining Transcat. In addition, 20% of our
calibration technicians and laboratory managers have earned the Certified Calibration Technician
designation issued by the ASQ.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Calibration improves an operation&#146;s maximum productivity and efficiency by assuring accurate,
reliable instruments and processes. Through our calibration services segment, we perform periodic
calibrations on new and used instruments as well as repair services for our customers. All of our
Calibration Centers of Excellence provide accredited calibration of common measurement parameters.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We utilize our Master Catalog, supplements, mailings, journal advertising, trade shows, and
the Internet to market our calibration services to customers and prospective customers with a
strategic focus in the highly regulated industries including life science, manufacturing, utility
and process. Our quality process and standards are designed to meet the needs of companies that are
highly regulated (e.g., the Food and Drug Administration), and/or have a strong commitment to
quality and a comprehensive calibration program.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The calibration outsource industry is highly fragmented and is composed of companies ranging
in size from non-accredited, sole proprietors to internationally recognized and accredited
corporations, such as Transcat, resulting in a tremendous range of service levels and capabilities.
A large percentage of calibration companies are small businesses that provide only basic
measurements and service markets in which quality requirements may not be as demanding as the
markets that we strategically target. Very few of these companies are structured to compete on the
same scale and level of quality as us. There are also several competitors with whom we compete who
have national or regional operations. Certain of these competitors may have greater resources than
we have and some of them have accreditations that are similar to ours. We differentiate ourselves
from our competitors by demonstrating our commitment to quality and by having a wide range of
capabilities that are tailored to the markets we serve. Customers also see the value in using
CalTrak-Online to monitor their instrument&#146;s status. We are also fundamentally different from most
of our competitors because we have the ability to bundle product, calibration and repair as a
single source for our customers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accreditation process is the only system currently in existence that assures measurement
competence. Each of our laboratories is audited and reviewed by external accreditation bodies
proficient in the technical aspects of the chemistry and physics that underlie metrology, ensuring
that measurements are properly made. Accreditation also requires that all standards used for
accredited measurements have a fully documented path, known as the traceability chain, either
directly or through other accredited laboratories, back to the national or international standard
for that measurement parameter. This ensures that our measurement process is consistent with the
global metrology network that is designed to standardize measurements worldwide.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To ensure the quality and consistency of our calibrations for our customers, we have sought
and achieved several international levels of quality and accreditation. Our calibration
laboratories are ISO 9001:2000 registered through Underwriter&#146;s Laboratories, which itself has
international oversight from the ANSI-ASQ National Accreditation Board. We believe our scope of
accreditation to ISO/IEC 17025 to be the broadest for the industries we serve. The accreditation
process also ensures that our calibrations are traceable to the National Institute of Standards and
Technology or the National Research Council (these are the National Measurement Institutes for the
United States and Canada, respectively), or to other national or international standards bodies, or
to measurable conditions created in our laboratory, or accepted fundamental and/or natural physical
constants, ratio type of calibration, or by comparison to consensus standards. Our laboratories are
accredited to ISO/IEC 17025 and ANSI/NCSL Z540-1-1994 using two of the four accrediting bodies
(&#147;AB&#146;s&#148;) in the United States that are signatories
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to the International Laboratory Accreditation Cooperation (&#147;ILAC&#148;). These two AB&#146;s are:
American Association for Laboratory Accreditation and National Voluntary Laboratory Accreditation
Program. These AB&#146;s provide an objective, third party, internationally accepted evaluation of the
quality, consistency, and competency of our calibration processes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The importance of this international oversight, ILAC, to our customers is the assurance that
our documents will be accepted worldwide, removing one of the barriers to trade that they may
experience if using a non-ILAC traceable calibration service provider.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CalTrak<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and CalTrak-Online are our proprietary metrology management systems that
provide a comprehensive calibration quality program. Many of our customers have unique calibration
service requirements to which we have tailored specific services. CalTrak-Online allows our
customers to track calibration cycles via the Internet and provides
our customers with a safe and
secure off-site archive of calibration records that can be accessed 24 hours a day. Access to
records data is managed through our secure password protected website. Calibration assets are
tracked with records that are automatically cross-referenced to the equipment that was used to
calibrate. CalTrak<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> has also been validated to meet the most stringent requirements
within the industry.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Risk Factors</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An investment in our common stock is highly speculative. You should read the &#147;Risk Factors&#148;
section beginning on page 8 of this prospectus (along with other matters and documents referred to
and incorporated by reference in this prospectus) to ensure that you understand the risks
associated with a purchase of our common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Our Contact Information and Website</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our principal executive offices are located at 35 Vantage Point Drive, Rochester, New York
14624. Our telephone number is (585)&nbsp;352-7777. Our website
address is: <U><I>www.transcat.com</I>.</U> Except
for any documents that are incorporated by reference into this prospectus that may be accessed from
our website, the information on our website is not part of this prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Selling Shareholder</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On April&nbsp;3, 1996, we acquired all of the outstanding shares of Altek Industries Corp. from E.
Lee Garelick and another seller. As part of the purchase price, we issued an aggregate of 170,000
shares of our common stock to Mr.&nbsp;Garelick. We delivered 56,666 shares to Mr.&nbsp;Garelick at closing
and the balance of 113,334 shares were issued to him on February&nbsp;11, 1997. On July&nbsp;22, 1997, we
distributed additional shares of our common stock to all of our shareholders in a 2-for-1 stock
split in the form of a stock dividend. As a result, Mr.&nbsp;Garelick received an additional 170,000
shares of our common stock, for an aggregate of 340,000 shares. Since 1996, Mr.&nbsp;Garelick has
gifted 139,000 of such shares of our common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Garelick, who served as a member of our board of directors since June&nbsp;1996, retired from
the board on May&nbsp;6, 2008. As a result of Mr.&nbsp;Garelick&#146;s retirement from the board, we have agreed
to register the shares covered by this prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of a registration statement that we have filed to enable Mr.&nbsp;Garelick
to resell up to 247,906 shares of our common stock. This amount includes the 201,000 shares of the
total number of shares he received in connection with our acquisition of Altek Industries Corp. (as
adjusted for the July&nbsp;22, 1997 2-for-1 stock split) and an additional 46,906 shares held by Mr.
Garelick, which includes shares held by Mr.&nbsp;Garelick prior to April&nbsp;3, 1996 and shares acquired
since that date under the Transcat, Inc. Amended and Restated Directors&#146; Warrant Plan and the
Transcat, Inc. Directors&#146; Stock Plan. We are not contractually obligated to file such registration
statement on his behalf.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Summary of this Offering</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="67%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Issuer:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Transcat, Inc.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Securities Offered:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The selling shareholder is offering up to 247,906
shares of our common stock.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>NASDAQ Symbol:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;TRNS&#148;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Securities Outstanding:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As of July&nbsp;1, 2008, 7,185,540 shares of our common
stock were issued and outstanding.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Use of Proceeds:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">We will not receive any proceeds from sales of our
common stock covered by this prospectus. The
selling shareholder will receive all proceeds from
sales of common stock covered by this prospectus.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Offering Price:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The offering price for the shares of common stock
covered by this prospectus will be determined by
the prevailing market price for the shares at the
time of their sale or in negotiated transactions.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Risk Factors:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">An investment in our common stock is highly
speculative. You should read the &#147;Risk Factors&#148;
section beginning on page 8 of this prospectus
(along with other matters and documents referred
to and incorporated by reference in this
prospectus) to ensure that you understand the
risks associated with a purchase of our common
stock.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Terms of Sale:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The terms of sale for the shares of our common
stock covered by this prospectus will be
determined at the time of their sale.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RISK FACTORS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should consider carefully all of the information set forth in this prospectus and the
documents incorporated by reference herein, unless expressly provided otherwise, and, in
particular, the risk factors described in our Annual Report on Form 10-K for the year ended March
29, 2008, which are incorporated by reference into this prospectus, and certain of our other
filings with the Securities and Exchange Commission. The risks described in any document
incorporated by reference herein are not the only ones we face, but are considered to be the most
material. Additional risks and uncertainties not presently known to us or that we currently deem
immaterial may also impair our business or cause the value of our common stock to drop. In
addition, there may be other unknown or unpredictable economic, business, competitive, regulatory
or other factors that could have material adverse effects on our future results. Past financial
performance may not be a reliable indicator of future performance and historical trends should not
be used to anticipate results or trends in future periods.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except for historical facts, the statements in this prospectus are forward-looking statements.
Forward-looking statements are merely our current predictions of future events. Such statements
can be identified by the use of forward-looking terminology such as &#147;may,&#148; &#147;expect,&#148; &#147;intend,&#148;
&#147;estimate,&#148; &#147;anticipate,&#148; or &#147;believe&#148; or similar or comparable terminology. These statements are
inherently uncertain, and actual events could differ materially from our predictions. Important
factors that could cause actual events to vary from our predictions include those referred to under
the heading &#147;Risk Factors&#148; in this prospectus. We assume no obligation to update our
forward-looking statements to reflect new information or developments. We urge readers to review
carefully the risk factors referred to this prospectus and the other documents that we file with
the Securities and Exchange Commission. You can read these documents at the Securities and
Exchange Commission&#146;s website at <U><I>www.sec.gov</I></U>, under our company name or our CIK number:
0000099302.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not undertake any obligation to update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, or to reflect any events or
circumstances after the date of this prospectus or the date of any applicable prospectus
supplement, except as required by law. Although we believe that our plans, intentions and
expectations reflected in or suggested by the forward-looking statements made are reasonable,
ultimately we may not achieve such plans, fulfill such intentions or meet such expectations.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>USE OF PROCEEDS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The selling shareholder is selling the shares of common stock covered by this prospectus. We
will not receive any proceeds from sales of the common stock covered by this prospectus.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SELLING SHAREHOLDER</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On April&nbsp;3, 1996, we acquired all of the outstanding shares of Altek Industries Corp. from E.
Lee Garelick and another seller. As part of the purchase price, we issued an aggregate of 170,000
shares of our common stock to Mr.&nbsp;Garelick. We delivered 56,666 shares to Mr.&nbsp;Garelick at closing
and the balance of 113,334 shares were issued to him on February&nbsp;11, 1997. On July&nbsp;22, 1997, we
distributed additional shares of our common stock to all of our shareholders in a 2-for-1 stock
split in the form of a stock dividend. As a result, Mr.&nbsp;Garelick received an additional 170,000
shares of our common stock, for an aggregate of 340,000 shares. Since 1996, Mr.&nbsp;Garelick has
gifted 139,000 of such shares of our common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Garelick, who served as a member of our board of directors since June&nbsp;1996, retired from
the board on May&nbsp;6, 2008. As a result of Mr.&nbsp;Garelick&#146;s retirement from the board, we have agreed
to register the shares covered by this prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of a registration statement that we have filed to enable Mr.&nbsp;Garelick
to resell up to 247,906 shares of our common stock. This amount includes the 201,000 shares of the
total number of shares he received in connection with our acquisition of Altek Industries Corp. (as
adjusted for the July&nbsp;22, 1997 2-for-1 stock
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">split) and an additional 46,906 shares held by Mr.&nbsp;Garelick, which includes shares held by Mr.
Garelick prior to April&nbsp;3, 1996 and shares acquired since that date under the Transcat, Inc.
Amended and Restated Directors&#146; Warrant Plan and the Transcat, Inc. Directors&#146; Stock Plan. We are
not contractually obligated to file such registration statement on his behalf.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents information regarding the shares of our common stock that are
owned by the selling shareholder and the shares that he may offer and sell from time to time under
this prospectus. The term &#147;selling shareholder&#148; includes Mr.&nbsp;Garelick, as well as his transferees,
pledgees, donees and other successors. The table assumes that the selling shareholder will sell
all of the shares offered under this prospectus. However, because the selling shareholder may
offer all or some of his shares under this prospectus or in any other manner permitted by law, no
assurances can be given as to the actual number of shares that will be sold by the selling
shareholder or that will be held by the selling shareholder after his sales.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Shares Owned</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Shares Owned</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Before the</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Number of</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>After the</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Selling Shareholder</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Offering</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Shares Offered</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Offering Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Percent</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">E. Lee Garelick</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">247,906</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">247,906</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information concerning the selling shareholder may change from time to time. We will present
any changed information in a supplement to this prospectus as necessary and required by the rules
of the Securities and Exchange Commission.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PLAN OF DISTRIBUTION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The selling shareholder and any of his pledgees, assignees and successors-in-interest may,
from time to time, sell any or all of their shares of our common stock covered by this prospectus
on any stock exchange, market or trading facility on which the shares are traded. Our common stock
is currently quoted on the NASDAQ Capital Market under the symbol &#147;TRNS.&#148; The selling shareholder
may also sell his shares in private transactions in accordance with applicable law. These sales may
be at fixed or negotiated prices. The selling shareholder may use any one or more of the following
methods when selling shares:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ordinary brokerage transactions and transactions in which the broker-dealer
solicits purchasers;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>block trades in which the broker-dealer will attempt to sell the shares as agent
but may position and resell a portion of the block as principal to facilitate the
transaction;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>purchases by a broker-dealer as principal and resale by the broker-dealer for its
account;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>privately negotiated transactions;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>broker-dealers may agree with the selling shareholder to sell a specified number
of such shares at a stipulated price per share;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a combination of any such methods of sale; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any other method permitted pursuant to applicable law.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The selling shareholder may also sell shares of our common stock under Rule&nbsp;144 under the
Securities Act if available, rather than under this prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Broker-dealers engaged by the selling shareholder may arrange for other broker-dealers to
participate in sales. Broker-dealers may receive commissions or discounts from the selling
shareholder (or, if any broker-dealer acts as agent for the purchaser of shares, from the
purchaser) in amounts to be negotiated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The selling shareholder and any broker-dealers or agents involved in selling the
shares may be deemed &#147;underwriters&#148; within the meaning of the Securities Act in connection with
such sales. In such event, any commissions received by such broker-dealers or agents and any
profit on the resale of the shares purchased by them may be deemed to be underwriting commissions
or discounts under the Securities Act. We are not aware of any agreement or understanding between
the selling shareholder and any other person to distribute our common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The selling shareholder and the company have agreed to pay certain fees and expenses incurred
by us incident to the registration of the shares of our common stock.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LEGAL OPINION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Harter Secrest &#038; Emery LLP, Rochester, New York, has passed upon the validity of the shares of
common stock being offered pursuant to this prospectus.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXPERTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements and schedule as of March&nbsp;29, 2008 and March&nbsp;31, 2007 and for each of
the three years in the period ended March&nbsp;29, 2008 incorporated by reference in this prospectus
have been so incorporated in reliance on the report of BDO Seidman, LLP, an independent registered
public accounting firm, incorporated herein by reference, given on the authority of said firm as
experts in auditing and accounting.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>WHERE YOU CAN FIND MORE INFORMATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a public company, and we file annual, quarterly and current reports, proxy statements
and other information with the Securities and Exchange Commission. Copies of the reports, proxy
statements and other information may be read and copied at the Securities and Exchange Commission&#146;s
Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You can request copies of
such documents by writing to the Securities and Exchange Commission and paying a fee for the
copying cost. You may obtain information on the operation of the Public Reference Room by calling
the Securities and Exchange Commission at 1-800-SEC-0330. All reports and other information that
we file with the Securities and Exchange Commission are also available to the public through the
Securities and Exchange Commission&#146;s web site at <U><I>www.sec.gov</I></U>, under our company name or our
CIK number: 0000099302.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We make available through our website located at <U><I>www.transcat.com</I></U> our proxy
statements, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form
8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we
electronically submit such material to the Securities and Exchange Commission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of a registration statement on Form S-3 that we have filed with the
Securities and Exchange Commission. Certain information in the registration statement has been
omitted from this prospectus in accordance with the rules and regulations of the Securities and
Exchange Commission. We have also filed exhibits with the registration statement that are excluded
from this prospectus. For further information about us, and the common stock offered by this
prospectus, we refer you to the registration statement and its exhibits, which may be obtained as
described above.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>INCORPORATION BY REFERENCE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Securities and Exchange Commission allows us to &#147;incorporate by reference&#148; into this
prospectus the information that we file with it. This means that we can disclose important
information to you in this document by referring you to other filings we have made with the
Securities and Exchange Commission. The information incorporated by reference is considered to be
part of this prospectus, and later information we file with the Securities and Exchange Commission
that is incorporated or deemed to be incorporated by reference into this prospectus will update and
supersede this information. We incorporate by reference the documents listed below and any future
documents we file with the Securities and Exchange Commission under Section&nbsp;13(a), 13(c), 14 or
15(d) of the Securities Exchange Act prior to the completion of the offering covered by this
prospectus:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our annual report on Form 10-K for our fiscal year ended March&nbsp;29, 2008, filed with the
Securities and Exchange Commission on June&nbsp;26, 2008;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our definitive proxy statement for our 2008 annual meeting of shareholders, filed with the
Securities and Exchange Commission on July&nbsp;8, 2008;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our current report on Form 8-K filed with the Securities and Exchange Commission on May&nbsp;9,
2008;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our current report on Form 8-K filed with the Securities and Exchange Commission on May&nbsp;8,
2008; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the description of our common stock, par value $0.50 per share, contained in amendment
number 1 to our registration statement on Form S-3 (Registration No.&nbsp;333-42345), filed with
the Securities and Exchange Commission on February&nbsp;5, 1998.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus may contain information that updates, modifies or is contrary to information
in one or more of the documents incorporated by reference in this prospectus. You should rely only
on the information incorporated by reference or provided in this prospectus. We have not
authorized anyone else to provide you with different information. You should not assume that the
information in this prospectus is accurate as of any date other than the date of this prospectus or
the date of the documents incorporated by reference in this prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon your written or oral request, we will provide at no cost to you a copy of any and all of
the information that is incorporated by reference in this prospectus.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Requests for such documents should be directed to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 30%">Corporate Secretary<BR>
Transcat, Inc.<BR>
35 Vantage Point Drive<BR>
Rochester, New York 14624<BR>
Tel: (585)&nbsp;352-7777

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may also access the documents incorporated by reference in this prospectus through our
website located at <U><I>www.transcat.com</I></U>. Except for the specific incorporated documents listed
above, no information available on or through our website shall be deemed to be incorporated in
this prospectus or the registration statement of which it forms a part.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PART II</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>INFORMATION NOT REQUIRED IN THE PROSPECTUS</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;14. Other Expenses of Issuance and Distribution.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Set forth below are the expenses expected to be incurred by the registrant in connection with
the distribution of the securities registered hereby. A percentage of the expenses will be borne
by the selling shareholder identified in this registration statement With the exception of the
Securities and Exchange Commission registration fee, the amounts set forth below are estimates.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Nature of Expense</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Amount</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Registration fee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">64.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accounting fees and expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Legal fees and expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">20,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Transfer agent fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Printing and related fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Miscellaneous</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">25,064.00</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;15. Indemnification of Directors and Officers.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Article&nbsp;VI of the registrant&#146;s code of regulations, as amended, provides that the registrant
shall indemnify its directors and officers to the fullest extent authorized by the Ohio General
Corporation Law (the &#147;OGCL&#148;). With respect to indemnification of directors and officers, Section
1701.13 of the OGCL provides that a corporation may indemnify or agree to indemnify any person who
was or is a party, or is threatened to be made a party, to any threatened, pending or completed
action, suit, or proceeding, whether civil, criminal, administrative or investigative, other than
an action by or in the right of the corporation, by reason of the fact that he is or was a
director, officer, employee or agent of the corporation, or is or was serving at the request of the
corporation as a director, trustee, officer, employee, member, manager or agent of another
corporation, domestic or foreign, nonprofit or for profit, a limited liability company, or a
partnership, joint venture, trust or other enterprise, against expenses, including attorneys&#146; fees,
judgments, fines and amounts paid in settlement actually and reasonably incurred by him in
connection with such action, suit, or proceeding, if he acted in good faith and in a manner he
reasonably believed to be in or not opposed to the best interests of the corporation, and, with
respect to any criminal action or proceeding, if he had no reasonable cause to believe his conduct
was unlawful. Under this provision of the OGCL, the termination of any action, suit or proceeding
by judgment, order, settlement, or conviction, or upon a plea of nolo contendere or its equivalent,
shall not, of itself, create a presumption that the person did not act in good faith and in a
manner he reasonably believed to be in or not opposed to the best interests of the corporation,
and, with respect to any criminal action or proceeding, he had reasonable cause to believe that his
conduct is unlawful.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore, the OGCL provides that a corporation may indemnify or agree to indemnify any
person who was or is a party, or is threatened to be made a party, to any threatened, pending, or
completed action or suit by or in the right of the corporation to procure a judgment in its favor
by reason of the fact that he is or was a director, officer, employee, or agent of the corporation,
or is or was serving at the request of the corporation as a director, trustee, officer, employee,
member, manager, or agent of another corporation, domestic or foreign, nonprofit or for profit, a
limited liability company, or a partnership, joint venture, trust or other enterprise, against
expenses, including attorneys&#146; fees, actually and reasonably incurred by him in connection with the
defense or settlement of such action or suit, if he acted in good faith and in a manner he
reasonably believed to be in or not opposed to the best interests of the corporation, except that
no indemnification shall be made in respect of: (i)&nbsp;any claim, issue or matter as to which such
person is adjudged to be liable for negligence or misconduct in the performance of his duty to the
corporation unless, and only to the extent that, the court of common pleas or the court in which
such action or suit was brought determines, upon application, that, despite the adjudication of
liability, but in view of all the circumstances of the case, such person is fairly and reasonably
entitled to indemnify for such expenses as the court of common pleas or such other court shall deem
proper; or (ii)&nbsp;any action or suit in which the only liability asserted
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->II-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">against a director is pursuant to OGCL Section&nbsp;1701.95 (relating to unlawful loans, dividends,
and distributions of assets).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;16. Exhibits</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following documents are filed as exhibits to this registration statement:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Opinion re legality</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Opinion of Harter Secrest &#038; Emery LLP</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(23)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Consents of experts and counsel</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">23.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Consent of Harter Secrest &#038; Emery LLP (included in Exhibit&nbsp;5.1)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">23.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Consent of BDO Seidman, LLP</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(24)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Power of attorney (previously filed)</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;17. Undertakings</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(a)&nbsp;The undersigned registrant hereby undertakes:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;To file, during any period in which offers or sales are being made, a post-effective
amendment to this registration statement:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;To reflect in the prospectus any facts or events arising after the effective date of the
registration statement (or the most recent post-effective amendment thereof) which, individually or
in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered
(if the total dollar value of securities offered would not exceed that which was registered) and
any deviation from the low or high end of the estimated maximum offering range may be reflected in
the form of prospectus filed with the Commission pursuant to Rule 424(b) (&#167; 230.424(b) of this
chapter) if, in the aggregate, the changes in volume and price represent no more than a 20% change
in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in
the effective registration statement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;To include any material information with respect to the plan of distribution not
previously disclosed in the registration statement or any material change to such information in
the registration statement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Provided, however</I>, that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;Paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the registration
statement is on Form S-8, and the information required to be included in a post-effective amendment
by those paragraphs is contained in reports filed with or furnished to the Commission by the
registrant pursuant to Section&nbsp;13 or Section 15(d) of the Securities Exchange Act of 1934 that are
incorporated by reference in the registration statement; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the
registration statement is on Form S-3 or Form F-3 and the information required to be included in a
post effective amendment by those paragraphs is contained in reports filed with or furnished to the
Commission by the registrant pursuant to Section&nbsp;13 or Section 15(d) of the Securities Exchange Act
of 1934 that are incorporated by reference in the registration statement, or is contained in a form
of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)&nbsp;<I>Provided further, however, </I>that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the
registration statement is for an offering of asset-backed securities on Form S-1 or Form S-3, and
the information required to be included in a post-effective amendment is provided pursuant to Item
1100(c) of Regulation&nbsp;AB.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->II-2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;That, for the purpose of determining any liability under the Securities Act of 1933, each
such post-effective amendment shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be
the initial <I>bona fide </I>offering thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;To remove from registration by means of a post-effective amendment any of the securities
being registered which remain unsold at the termination of the offering.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;If the registrant is a foreign private issuer, to file a post-effective amendment to the
registration statement to include any financial statements required by Item&nbsp;8.A. of Form 20-F at
the start of any delayed offering or throughout a continuous offering. Financial statements and
information otherwise required by Section&nbsp;10(a)(3) of the Act need not be furnished, <I>provided</I>, that
the registrant includes in the prospectus, by means of a post-effective amendment, financial
statements required pursuant to this paragraph (a)(4) and other information necessary to ensure
that all other information in the prospectus is at least as current as the date of those financial
statements. Notwithstanding the foregoing, with respect to registration statements on Form F-3, a
post-effective amendment need not be filed to include financials statements and information
required by Section&nbsp;10(a)(3) of the Act or Rule&nbsp;3-19 if such financial statements and information
are contained in periodic reports filed with or furnished to the Commission by the registrant
pursuant to Section&nbsp;13 or Section 15(d) of the Securities Exchange Act of 1934 that are
incorporated by reference in the Form F-3.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;That, for the purpose of determining liability under the Securities Act of 1933 to any
purchaser:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;If the registrant is relying on Rule&nbsp;430B:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;Each prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(3) shall be deemed to be
part of the registration statement as of the date the filed prospectus was deemed part of and
included in the registration statement; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;Each prospectus required to be filed pursuant to Rule&nbsp;424(b)(2), (b)(5), or (b)(7) as part
of a registration statement in reliance on Rule&nbsp;430B relating to an offering made pursuant to Rule
415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by section 10(a)
of the Securities Act of 1933 shall be deemed to be part of and included in the registration
statement as of the earlier of the date such form of prospectus is first used after effectiveness
or the date of the first contract of sale of securities in the offering described in the
prospectus. As provided in Rule&nbsp;430B, for liability purposes of the issuer and any person that is
at that date an underwriter, such date shall be deemed to be a new effective date of the
registration statement relating to the securities in the registration statement to which that
prospectus relates, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof. Provided, however, that no statement made in a registration
statement or prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement or prospectus that
is part of the registration statement will, as to a purchaser with a time of contract of sale prior
to such effective date, supersede or modify any statement that was made in the registration
statement or prospectus that was part of the registration statement or made in any such document
immediately prior to such effective date; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;If the registrant is subject to Rule&nbsp;430C, each prospectus filed pursuant to Rule 424(b)
as part of a registration statement relating to an offering, other than registration statements
relying on Rule&nbsp;430B or other than prospectuses filed in reliance on Rule&nbsp;430A, shall be deemed to
be part of and included in the registration statement as of the date it is first used after
effectiveness. Provided, however, that no statement made in a registration statement or prospectus
that is part of the registration statement or made in a document incorporated or deemed
incorporated by reference into the registration statement or prospectus that is part of the
registration statement will, as to a purchaser with a time of contract of sale prior to such first
use, supersede or modify any statement that was made in the registration statement or prospectus
that was part of the registration statement or made in any such document immediately prior to such
date of first use.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;That, for the purpose of determining liability of the registrant under the Securities Act
of 1933 to any purchaser in the initial distribution of the securities:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The undersigned registrant undertakes that in a primary offering of securities of the undersigned
registrant pursuant to this registration statement, regardless of the underwriting method used to
sell the securities to the purchaser, if the securities are offered or sold to such purchaser by
means of any of the following communications, the undersigned registrant will be a seller to the
purchaser and will be considered to offer or sell such securities to such purchaser:
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->II-3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Any preliminary prospectus or prospectus of the undersigned registrant relating to the
offering required to be filed pursuant to Rule&nbsp;424;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Any free writing prospectus relating to the offering prepared by or on behalf of the
undersigned registrant or used or referred to by the undersigned registrant;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;The portion of any other free writing prospectus relating to the offering containing
material information about the undersigned registrant or its securities provided by or on behalf of
the undersigned registrant; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;Any other communication that is an offer in the offering made by the undersigned
registrant to the purchaser.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)&nbsp;The undersigned registrant hereby undertakes that, for purposes of determining any liability
under the Securities Act of 1933, each filing of the registrant&#146;s annual report pursuant to Section
13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing
of an employee benefit plan&#146;s annual report pursuant to Section 15(d) of the Securities Exchange
Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial <I>bona fide </I>offering thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(c)&nbsp;The undersigned registrant hereby undertakes to deliver or cause to be delivered with the
prospectus, to each person to whom the prospectus is sent or given, the latest annual report to
security holders that is incorporated by reference in the prospectus and furnished pursuant to and
meeting the requirements of Rule&nbsp;14a-3 or Rule&nbsp;14c-3 under the Securities Exchange Act of 1934;
and, where interim financial information required to be presented by Article&nbsp;3 of Regulation&nbsp;S-X
are not set forth in the prospectus, to deliver, or cause to be delivered to each person to whom
the prospectus is sent or given, the latest quarterly report that is specifically incorporated by
reference in the prospectus to provide such interim financial information.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)&nbsp;Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be
permitted to directors, officers and controlling persons of the registrant pursuant to the
foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy as expressed in
the Act and is, therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrant of expenses incurred or paid by a
director, officer or controlling person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person in connection with
the securities being registered, the registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and
will be governed by the final adjudication of such issue.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->II-4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant
certifies that it has reasonable grounds to believe that it meets all of the requirements for
filing on Form S-3 and has duly caused this amendment no. 1 to registration statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the City of Rochester, State of New York, on July
23, 2008.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>Transcat, Inc.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="1" valign="top">By:&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/
Charles P. Hadeed&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>

    <TD colspan="2" align="left">Charles P. Hadeed&nbsp;<br>President, Chief Executive Officer and<br>
Chief Operating Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left"></TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->II-5<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Act of 1933, this amendment no.
1 to registration statement has
been signed by the following persons in the capacities and as of the dates indicated.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Date</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Signature</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Title</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">July 23, 2008
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Charles P. Hadeed<BR><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Charles P. Hadeed
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President, Chief Executive Officer and<BR>
Chief Operating Officer; Director<BR>
(Principal Executive Officer)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">July 23, 2008
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ John J. Zimmer<BR><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
John J. Zimmer
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President of Finance and<BR>
Chief Financial Officer<BR>
(Principal Financial Officer and <BR>Principal Accounting Officer)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">July 23, 2008
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">*<BR><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Carl E. Sassano
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chairman of the Board of Directors</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">July 23, 2008
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/&nbsp;Francis R. Bradley<BR><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Francis R. Bradley
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">July 23, 2008
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">*<BR><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Richard J. Harrison
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">July 23, 2008
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">*<BR><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Nancy D. Hessler
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">July 23, 2008
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">*<BR><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Paul D. Moore
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">July 23, 2008
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">*<BR><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Harvey J. Palmer
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">July 23, 2008
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">*<BR><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Alan H. Resnick
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">July 23, 2008
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">*<BR><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
John T. Smith
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
</TR>

<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">July 23, 2008
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">*By: /s/ Charles P. Hadeed<BR><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Charles P. Hadeed, as attorney-in-fact
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->II-6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>INDEX TO EXHIBITS</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(5)&nbsp;&nbsp;&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Opinion re legality</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Opinion of Harter Secrest &#038; Emery LLP</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(23)&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Consents of experts and counsel</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">23.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Consent of Harter Secrest &#038; Emery LLP (included in Exhibit&nbsp;5.1)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">23.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Consent of BDO Seidman, LLP</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(24)&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Power of attorney (previously filed)</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>l32474cexv5w1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;5.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>OPINION OF HARTER SECREST &#038; EMERY LLP</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Harter Secrest &#038; Emery LLP Letterhead

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">July 23, 2008

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Transcat, Inc.<BR>
35 Vantage Point Drive<BR>
Rochester, New York 14624

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">Re:</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Registration Statement on Form&nbsp;S-3<BR>
247,906 Shares of Common Stock, par value $.50 per share</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ladies and Gentlemen:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You have requested our opinion in connection with your Registration Statement on Form S-3 (the
&#147;Registration Statement&#148;) to be filed with the Securities and Exchange Commission relating to the
registration under the Securities Act of 1933, as amended, of 247,906 shares of Common Stock, par
value $.50 per share (the &#147;Shares&#148;) of Transcat, Inc., issued to E. Lee Garelick.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are familiar with the proceedings undertaken in connection with the authorization and
issuance of the Shares to Mr.&nbsp;Garelick. Additionally, we have examined such questions of law and
fact as we have considered necessary or appropriate for purposes of this opinion.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based upon the foregoing, we are of the opinion that the Shares to be offered and sold
pursuant to the Registration Statement have been duly authorized, validly issued and are fully paid
and non-assessable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We consent to your filing this opinion as an exhibit to the Registration Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 50%; margin-top: 12pt">Very
truly yours,<BR><BR>
/s/ Harter Secrest &#038; Emery LLP
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>l32474cexv23w2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;23.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Transcat, Inc.<BR>
Rochester, New York
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We hereby consent to the incorporation by reference in the Prospectus constituting a part of this
Registration Statement of our report dated June&nbsp;23, 2008, relating to the consolidated financial
statements and schedule of Transcat, Inc. appearing in the Company&#146;s Annual Report on Form 10-K for
the year ended March&nbsp;29, 2008.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We also consent to the reference to us under the caption &#147;Experts&#148; in the Prospectus.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ BDO Seidman, LLP
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR><TR>
    <TD colspan="3" align="left">BDO Seidman, LLP&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">New York, New York<BR>
July 23, 2008

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>l32474cl3247401.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 l32474cl3247401.gif
M1TE&.#EA%0$]`/?_`!04%/W]_1(2$@\/#Q,3$PX.#@T-#?+R\F=G9PL+"P8&
M!H"`@!`0$/#P\/GY^3`P,!$1$186%E-34PP,#/KZ^LW-S;>WMYJ:FAP<'(^/
MCRHJ*@H*"@D)"4)"0E]?7^OKZ_S\_"LK*_'Q\?CX^/;V]N+BXO?W]^GIZ7-S
M<W5U=?7U]71T=$Y.3N[N[@@("&9F9EI:6OO[^UA86.KJZA@8&./CX^WM[514
M5)>7EW%Q<:&AH965E0<'!^_O[VIJ:JVMK?/S\WAX>,+"PJBHJ$]/3U965F-C
M8TA(2%!04/3T].CHZ$='1TU-35=75WU]?4%!0;R\O,#`P.#@X+^_O^SL[!L;
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MA\G)R30T-$-#0];6UCT]/=W=W2`@(%U=77M[>]75U3@X."$A(=34U(6%A1H:
M&M?7U[.SLSP\/*.CHXR,C!<7%Z:FIH2$A(&!@38V-K*RLBDI*6UM;:RLK$1$
M1`4%!;2TM)24E%Y>7D!`0&MK:R(B(B0D)#(R,@```*6EI5%149R<G(B(B)Z>
MGKJZNJ2DI']_?R<G)Q\?']O;VVYN;@0$!"XN+IV=G24E):^OKQT='0,#`]_?
MWP$!`0("`A45%?_______R'Y!`$``/\`+``````5`3T```C_`/T)'$BP8(""
M"!,J7,BPX<&&$!D&>"C1(<6(`B]^&+1IAR\R.EQ5(G@1(L41:B1]TR+'V)U`
M@%15:$%R84F,.!7>)#$BH\!_.&.0,8*@J-&C2),>-8+GV8L72J,6?='J5)0#
M.1?V"()%Z1A._BB<(GKT!984/?S=-.BOU)^H9U4D5*+CBX9^!A)LV&!`P#@F
MF-YD%6@"2J!+&`8D<.%"+P\.!J;M,0:ID$-_0XQ`1?K"R*95;Z6*1FK$6\%2
M/N[\">)L(%",%`294T"[MNW;N&WO&U6M6[?<P&USH'$E58G!!1?YSFVNC+\1
M1V;C[A8$)R'IN/.%24NPQ:I<!EP,_X!``(!Y`@(&<$AP[1$(G",<&8K`8P*#
M\@#ZZ==/`$(!'@64H\=("\%23#[`[;,"$=@%YR!MW?"#!T'I($&-)5Y<P(L#
M/^%$`1(#["?BB"26R(`=J9A7XHHB`@#!!BZ@T@N'R`F!`00K)K"`/PY(4$")
MY6&#D2H"Y$>B`"$T0-`6W&R0``$LZ@=``@4@<$)$@TB@G@!1CDB``3SL$LU%
M#QW`0@(L,N`$#"%VZ28`#'`Q$!M$(&*-''+H($L['<(&HIN`GIBBD8"6",`$
M$_PA6%8M"&(`BSKRZ..*!:#"2$1#%%DBDDH*),DX+D!9*`$N$$$)0R#@H$RH
MA8YX*`,($/^#$"`3$$JBFFRVRB*<<@HT"0XC%"'$%*.T\$<,_KP6T8=MZFHB
MBBHZ.V($I"YQG$D/65,KI#OV^&..9U``4::V[L>I0)I\\JBS`'`@0Q(('22"
M/`8T*ZU^`O!PS;4"@1(&CFFN:>^]_?`Z4`Y3J,"$'T<$$<,92BH+$;,$CRAH
MM!5+R<$2IUKD3Q15<,FMI-\".4`O%9&[:9+^4)++!`0?J@=;)Q3!@:@9]S-!
M$4`,U(.C7>(Z\+T&"R2&+"08`44PEWI`0K(>_IES/Q>7FS$''IAP60_!E)QC
MMY.F:0\;#>D`@=7]("F"/V4D@':A$(1104$MH,/!V\X.$$(B!+G_LVZ40D]=
MM#\_S-*`#R-@@L<)Q_2YK-0Y5SWU?@04@$9$76P;9:3>=ID`$CVOY0\A?X^(
MI`IJ*`/PKGCKC`5!)F"Q0>NMNOB(6@*Y4L7J`>>:\^`J8!'$%&$]TH04CD],
M1`'F-8_QBLXW/X`@@[+N/*`#[($\0V;$(?+F8'MMZ`2`X)X0#J6+*(`H*C"3
MONDN<,"#"]^;K@S?`J6B^=0)@"/N03.`QOM,Y`1%,"]ZM$,@`09`!H(HH15G
M"$(*2-$KJ,'F"/-(@`8WZ+8HY86#">@&'P#QO!$58#T:W``/$E"_$DU@0EJY
M@OB^1C(WQ4T3"T'?B@2P!R4\@0$L@D`$_[[`!3S(@`8XLU@Z!`(RWNT*`@P8
MP'B2J!\&B((5YD,!S`+E!`ED$(1/BE(!0+@!!4P"(15P!!TNY9J@<$(:&8BC
M''WQ"2I*B08IF(,<XT@&531"4RLZ`Q[($,=)Y"`<Z8D`BP;0B4XEQ!U;=!/G
MPM:E"7"#.PC1X:8>X(5BV)$_<;C=0-)1L!(50!O^2,(2(LDB`DQ@`Q%0!CD^
MT8P"B,=(!&"`#M1RD"STXY,E&D`7;B$-+NSQ%.K8PR?SLP8][I$,><"(Q)`3
MEA"TD#\8$(9",'$V0P$@"P@QP29"`$3H50&';(F"]PHUR1FN:`)B4(@FC[0+
M1]#@;0-X'4$H$/^,H?5C`$SP1ST&T#H`&,``5P`$*&I@@QE8PA$^\`0'@)B`
M<.$.#N7PYXH&L*.$@(`;Y715!(B7$-$59)H524@/-'#-7V)@;@GA)MK,\P.%
MQ*(*;X/3Y1!"A7`80)&`:F>A!$`#"YQO@&D#!B9***4!++$@VIC'7J:ZEWD,
MXPU\T"A_-G`-'3BR((FH0QQXL#?<!6`-K'031Q4"A`[X$P`1B$5)34H0E`ZF
M`2P%TDL5<@%`NHH`-54(#-RIGPD$8B`3$4CF:"<BH1:J`,E8%$'F:;I=[("I
M!1M`/7PBD$AP8PE'"*UH@^$$2)2GE0:XP_88$HM.[!)WFR``,#?:483_',"M
MAHJ`4:EI0=[Z`Z\M)<!>$]+7F0)V(80@+%[N@-B#N&*=K7)LH2;@@Y)05GW`
MZ$4I3=2$GE`$!`Z@@'C'*]X`W`"I!2M`&7H2D3>(2R"ZL(56::N0V[Y5M[ZU
M:U:`JU>8(J2XACJN0M@1@;<50`;(&L@'?.HLZ0(*/:HHR'7-58X?Q`&8<-(#
M70E"#&6T5#\&&(-WLT*!,VQ`6FM-B'USNUMJZC<G_"61</U;$`"3"``"3@@;
M,`#,`GSA(EI`4X/#YRP&A"`>YILPOFR1"67,-I?:X)=)=>!7$44``K98+4X.
M$@D&,)9$*;8M;F^,7]Z^&"<Q]M)P_UOE_>`X_[`)&405@#D!!!`D%-`U%`T[
MYZP)R(!#!U%RVO;P`3\H-VT;V$,UM,D06A`6``68@S_>DQ5D6"&DN@IS059,
MYA8CY\P82;.(9LS7-DLIQPBA1C=+9``M#(0*,DS3VQQ<*``,8!4#$?3Z2-"+
M0^NG`!L8AQ%*H1`2+`'3(H*`!FI@/OC(0,@FFJVF"<)ID7IZ,*".B*@IM^8:
MF[I@J/9)`$CQ:`%$8B!U2*N("M"!5WR2UH5B0#%J(1!=A^``-GB%KS/K@@@T
M(9K-_D`V/ER`,6R8+?[X!D$W>@UETE?%8[9V?GTKD&UCD\8$L?%?Z:`0-&Q7
MQF'P@D#P_&$(?"(4=O]`MG[@[>8H3>`)'Q@=89&4%B)]^$@\4`8@UC805N`#
MF`R0=$X.`HM/,`"H(X*`,N[Q!"?N9]H#J7:+RNQBBO\VKS+N=L:_C>-G%,0$
MR'!"')S^]"?`RP:7>+0!,D""*ZB\'RS?S]OWDX`T^`,-2*6Y0%`0QD(-8`-,
MR,1`\M",90)`%H-)`A/4O9\7-F`49/]G;3<=\:E?.RO9AHC%78KQ@6B\10`P
MAB^J48T@O&`)Q=A`Y$%\1G_4`;T&,$021.#V$L6=`4M(.]*])(!;1&+F+/,'
M$,[`@9O?F`.>&()`W(!$/8,S*Y,PP-L,\(0>V*`3D8>Z0*3N9JI_VNJ;)S7_
M<;\-8@[LA0,NV("7`9<-7?@C%!'XL`":L05_M*#V)(J[`1!@AG\M<A=K('_!
MYP\'(`<3L&_KU@]R`@4%%F";D!5]@`$?1@#3P`[^<`+8]W!B=E^7EQ.9UQ#A
MIW6>1WX%<SUOD@#JX`\SD'8L,@&N9G_X-R)Q5W#^0`;,PR("L'NF,X!AL0.>
MP`/S93$0D`&',&>&P@"XAA,'T#60L@("@8'9-WG45GG=UX$X\8$,$8*=)Q"?
MES,;0Q-U`&U@E@Q7`H-O-X,>X`\J<`-B^%<XR(,"@0R!\`D*8`"SE6QQ0`OP
MT&-RD!.0A$^[P&P7F('!)(511X52XGW8!GY8IV9;_^@/71@S&P`,B.`/L=!\
M0$(`MS`0]W>&1&9*:>@/PJ`!0;A#<#@0EA`$P#``+C!WZM,/TQ!$R4`3$?%<
M$P@!$?:$A`AFAKA]B%@PBHAYC!A<(LB%)-@J!,`!?-`&_J`$`I0FLT!M,=A8
MGT@B!1"*_A`-`G"'IOA5"/$&0V`,\,`!J\<?48)CDM!L\>(/'S`,/[518T`0
M-@!Y&DAY'#AQ%*>%I?9E4:(8I""(@<!X^)(-;4`"*G"0<#`,GEA#H#@0,;`&
M;0@HYP(1L#`+<**#NE(`39!@#!$($6DNGF`)`1`#)$D)NS@BVD>`OPA75BA-
MP]A?^U@Q[3(.C4`C%C`--_\'`,4`#;G0D\GP"CAE>]5H0J%X$(60"PBH/J+P
M7CI!$9Q0#*[X)@1`#0WQ#+_42N3`!(:PE8;`#?B`3[VHDO=H9B^9=8\8B;56
M!2]`-@*A!"P8)5^"*(ABAWM&2419$))`+;I"`)X@!+!0`8`9F!7@!;1($$/0
M@*WT<19C!8/`6>93`_K6)02@%U/5=X587RL9C!Y8EHX8D_<B`)[`1FJA#0))
M,&B(6$;SD5$2`6$`#V'PFK")#QB@?`AA!/-%'AYT#8?`%B`@#B<V.4\7EMR7
MB"T9$5BX$/HX?GC#C0Q070*AC=PX9`QIC=B(.S;P!$FY'U#$`-S9G0PP`4)7
M$)S_<%HW1@.S,`YWF`#9<`X(,02R!9S!B9EC677YV(BC5HR02'[3,`U1V1\X
MX`^(\`ZE*)U\1IT)H0F[,SD%P%P(L0WDZ255\`M_4)H@)@!WD`<))@Q[,*!Y
M(YR969P0<9P*D9QL-E,8X`2>,%\"4`6.(`'H53&GF1"^('U3`YJ641!KH%$`
MT`QMT`?-8'P`(``;T`SH,`E#8`@46C$I.9S`"*(-(:()0:+>-E,TD`>W,`WE
M2![E"*-#N6[521`J``8OVBK"5!#/@(DD`@'T$'-!L#\WIA\08'[U`I\HZ:'S
M^7WU28QGR74T$`4)=Q]1<HQ<.IUWJ1!%)T1OXHH$$`%=_U`)("`"U'!I+&(`
MSOD!':":-_:@="IY\LEB^.A;4KIU5.H&:B$&;KJI(U.@A:H0.[!PYS@.)VDZ
M$T`/3``-`J!<^0$%N-,']C"FV,,!P!JLPKH!YG=S2_JAG\I;H3J"HRH0)#`&
MO[F74C2MU$JM>!.C"F$"S]8E`H`*JJ"7T'-"$V!\!H`$-"(0=%`%'+HBRL8"
M[OJN\,H$+``&Y`!,QWJGBYBG,*F<AD(#I"H0'[!*>PD`[V`%!GNP"&L%GD`#
MJ6J77MH0SA`"*KH'!W`'F#I4<6`&".$(M40P*QH*(!"R(CNR(6L"#AN?$(>O
MPJBO9NF9KN*O!)$(J."K4E(`C?]:`CB;LSI;`I8`#)&'K27E#Y``J*:8!/H@
M"MEY8PG0.!3Q$$_90;IB4(L0$0%@"H1UKYY*EBS;F?Q:GO^*.[5`#@@X`3>@
M-0UQ`/0HE(3ZL`T!`A#YADKB#7&PKBW"`3>`%632+Y?@`ELZ(@8@"%@Q,3=P
MM7::M?0)JO;);7O:K!EQ$-M``U'9#P5`#TBV81^0##_;I?MQC1$!F<#7*3HP
M#4DJ8RYP!(*X$)30"OU`/Q*)`;L9$3$PN/4XA2J[F5M[GXO;KU]K/JO``#>7
M@_?@F`IQN9F[MIO[I4&;ERTUD803`CQ@?&YF`!M`"G"`$:4@`?DR`+,%::D0
M%+)[F2G_:[AXZEL]\`E\<5#H.T8`T)@)00CGB[[H.P$0X`H*(08)`+_XRP$Y
M@!,S4`Z0@;\'E0^-XP`LP`,`?%`*H`@')Q!:P`$3`,`;0`Z8Y`_+(`/9:VK]
MD0`\D`UL9Q(#00%9``[V,`$*0"4,0!X"(``,P`%@\#2PP0)U",#_\8*VM;<'
M/`$#\'R'RULBT`%[\`!`',0/0`_7P(P)T0ZB8`M"',2VL`N@L(XDX`,AL,1`
MO`=^4+T880-$(`I4#,3OT$`.\`(:T,4/D`TY0&D0(0(WP,5+O`?<$+@.B0U?
M\`FVI`",X0*/40!A\`1Z@$74I`;KX`-7\`X80#5$!0^Y``LY_T$!"##&7:P!
M&<!63<#&2VP+J$!2.XP<$P$$!]#)GGP`(M``!\"17R<"(O#)GRP"3-E<:G'*
MJ!S*6K/`:@$$KHS*!]``3Q,`LV?+G2P"*B#+/%++GPP$HL,*CK``=Z`(B@`#
M:Z`'U)`)9CL8B340)"`%AP`%MY`%0H`(-"'+$Z$"PNS)L*P3M,S+H'RNXVMU
MZKS.[-S.[OS.\!S/6BO/]%S/]GS/^)S/^07,%#?-OL7/-A'06R81`"W0^3S-
M:U'0^FP0_Y"WK+R.#QVT$MVX-Q$`(.#0J)G1)>'/ZLA+*?71'[W136L0HI-8
M$Y'0)?T0)=V4)"V\E]'1)^W2'BP0(/^@+"Z,<"\]=,X:T`\A%QVM$PA'`@>Q
MT0+ATR2]P"2PRB#MT4"-$#[]$!>=%0>7TIS%T49-M?&BTDVM$#X-%(TP"S(@
M#GZ,#%IP)8R`!N]%#+W0`]*0!BL@!E+@`'J``BF``KKJ#UNA!E.``BBP`CEP
M#MA`/,L@#C)P!T^L"<P@+LN@"@]1`CD``W<P-SN0`X&0!ES0`EU`URBP!9L@
M5_[`!A<`"Y#0C'4@`V-`;)M`"X&``HM@`VJ``%]`"Y?"T27@!"O`UW@P"'6P
M`BF0!E!``5R@"*3`"4IP#'R-`@M0AD"0`6*`/P+1#J=P$"30!5O@#+R=`BO0
M!_X0`[Y`;/[_X-A?@`!M$`/?4+T4D`Z,8`8YT-MS``2)@-W8#0I9P`SP0@%D
MP`DSL-LID`.E@-A:PP;GL`DYL`(KT`I"X@]M``DDH`?UYP`ZP%`I``-&\`ML
M@-THD`8[8`:\C0+J\`$6$`H"P0ZEL`Q!L#W;(`U)P`5I$`@Y@`FZH`7'\0$7
MP`YE0.!I@`8]L``R<`P'\`\[8`ASP`:`<`1KLP@$$&%]``9F"PKH4`-'``E;
M@`*S,(_4(`2/\`3N]P/]H`=PX`8((`.N@`QUT`A4(`C2P`;U<`5JH`,<L$O>
MX`,TO0(+(`4[@`M40`2KL`51X`5O@`KW(`2]P`O6``,'H06+(`G&_V`"1.$%
M/]`);2`/@:`)9M`'QM(+M?T"%`#5%6<&0Y`+Y]`'[/`$KB`$45`"0_`%B0`%
M'=`'0J`#K_`#6P`OF+$&S.`<`X$%57`IM9``%^`-O&`&9A`%U6L)Q:`(XI(#
MBU`)A$`$,[`$EO`<N%`+<Z`-0A`*N$`(;F`'4R`$9E`(QS`!N\D*`)`#K#`*
ML3`L4D`(/'`[=``.R.`*1>`#KL`*!W$+QB`"(?`$JDP*F8`'95`).@`&RQ`%
MUK`$4)`).]`$4>`&'K`(>M!ZOH`'6:``EZ,"T)`,'_`$D$#J/3H`<,X(AN`%
M42`&8``%;'`*:\`(7Y`!_P`,@B<0G-``+?_@`>KP`OXP"*9@MGD``W!P`UM`
M!>N0`C;@!Z="!;S`C#ZP`S?0,SM@#0*Q`!>@`_KD#^Y0#:=N""?@"ON[W1ZP
M`)8Q"`W0!&8P`EKS`<&`%2?``E/`!,3@`(:P#.PP"X-@")TR!=:]#F0?`R1`
M!)@P`R9P"!RRX`;_:C<P`_Y0"T5P`"/0$ZM@"FH0`(@@&'"`"[+>+S"0`HY`
M$$$0#M'@#\R0#-$@"2]@`HOO*\QP`Y7H`7I@&;^@Q94X`E^0!SN`,OZ@![XP
M!4XS`ARR"+O0"/Z@`[;@!&K``C90^H0@KY0@"0S:!3O52UA@`S!P`PUT!VS0
M"BDP$K\`+Q:P!@+_T0M.4&\KH`Z17(/28`'`8&=><`5(,`-@T`9D[P^_<`1+
M,`64@`0Q1P>T(!!.@``'`!`?V/PC!\3?P8.WSE3H(`66*1,'\\`H=,34BU<9
M#EPZ@R*8L1BZCB0"8\%?!BT'%V!RMPKA#W&13I$1XR8-0F<>P!2Q0`$7DQ=C
MZ#1`]2(-'P0@4$#R<B.`!1^RQB`\F.,*@C&`_/4IPHO4H8-J^IF3@;`&KDK^
M?CTX8^2%,"!UF+"8,\*?+B(?J%JP]Z2&,X1!%K4"\@5%I%#EC/R1`V<$F#YK
MI/E;!@Z,!`LFB"SS-^)+'S2"TIRQQ48(JC]&9E6JED9;BQS:M.BRY<$(_P(I
MA*SA""+IQ4$QC?P%".`O"Q8;'FH1J>"C38T_O-#1.2@+R\%'HUK-0@4%4(:#
M7*0]NX,@488R,CX(NH'%`Q0OQF))0"3AC;\A<@Z>D.,'08U_1)$"H0L^D.,2
M#[*)I(TBBE,+AAJ*L&0$2\))Q`XZ!HD&B0/0>,`#8&XZ)25_%KA@AT`0.N48
M2``!PI0@RCB(A`K\J6&389R!01(;9C#A@TLL.&2=(I((Y05KOC%N#3.(H*"Z
M058@I(491&B`#7\8(420&?QI8`PK'C$++7]`N8$2*CZ@P!(@6A#"#VKNR@NA
M$I@`I94C,$%HA1_D6*>.#.JQX(\//J#"GRDT(/_E"2)LR"2`$ASI!!$6U!A.
MACQP*.,0(9K@)`H83C#4GRY6J6,'>=`(@A4P*BDT@$:Z(*$)6GP`3CB$CFL!
MAA8@(>6,0VJD1)9A8/%'EM_\26>,7VHQ`@U?P/.'#'6P06$50%[`QI03P,B#
MBAD<R*.)`%*@Y8;[\O,'A`HH$*:,+_Y!P8<M5(C&CDS\\`(.'8K8@A=B"CEA
MBR)J0$((*J!X(IXE"O%'A1N:>J8&3;B9X90@#M)B!V*&B<6$0SK8(A(]_($"
M'G$..@`)ZN!8@D%OJ%!"9CX:\$<$%HA)XHA<=/'GF3.H0.("%;P8)9,<YK!!
M5&(ZR,.?-NRXSQ\22AC_KK@Z!]R"!3AF."&)8\J@P($7UO$G'C^Z#(L7$H0P
MX!R$:(%BAW=BF>."+,"9P6L1Y)FC!C7\\*8(Z@IYPAEPR%#!#4$H.45/?_"8
M)(HBE/`ZB3K0H..31]I!00T[I)A!"170\\>,9CPX*!!I#WIFC!9,*<0!4CSQ
M0A%(_/F`EZ?I^.,@-.K`3HQHB#CA#72VD44<2U"1`Q$F3EBBE@^4Z$$3=$!X
MXY573O#G'`36?0&\323XYP`LH'D%%U9*T<K+'.9KHHE6S.CB@S5PD:&)*)*0
MQV$5B$$'*P#!08*@B6W@X""8V(0_0A$,8/!!%?ZXA9A(A0>$U,(.?`A')"B0
M_P(DP*`(95""#VS@#R"T(A/^:,1-_*&)1?A#&"S8Q1.P<1(_P$`&1M!'%H;!
M!T%D@2H(*8X24G`?9!"A"8HP13N4<(91\*$,![`1"EJ`$`?X`AHRF`,MU):!
M0:CA!@=PQ"T.`089*$(&.O"!]U@8B5\(XH>1D*$?RL$';_C#$=LX"">X``L6
MI+$(/[@`'93P!2E(HA%P0,(2)<");>S@((OHPD%V,`2J;*$:(M""]Q#1!"D@
MP@_0X,,.GA0%9E1'28C2P@%2L(MK+"`&;IB$`^1@@1*DH`=KD``,3(&'3(C!
M+C\8PPE+,8F#Q$,"EV`",O[Q3&A&4YK3I&8UK7E-;!1F4YO;Y&8WO?E-<(93
)G.,DYS,#`@`[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
